Clearside Biomedical Inc (NASDAQ:CLSD) Director Clay Thorp sold 68,485 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $6.56, for a total transaction of $449,261.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Clay Thorp also recently made the following trade(s):

  • On Wednesday, February 22nd, Clay Thorp sold 27,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.55, for a total transaction of $203,850.00.
  • On Friday, February 17th, Clay Thorp sold 41,485 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.60, for a total transaction of $315,286.00.
  • On Friday, January 20th, Clay Thorp sold 68,485 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.53, for a total transaction of $584,177.05.

Clearside Biomedical Inc (NASDAQ:CLSD) traded down 0.87% during trading on Monday, hitting $6.87. 192,340 shares of the stock were exchanged. Clearside Biomedical Inc has a 1-year low of $5.44 and a 1-year high of $25.08. The firm’s market capitalization is $146.67 million. The company has a 50-day moving average price of $7.51 and a 200 day moving average price of $12.43.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Tuesday, March 14th. The company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.12. Equities analysts predict that Clearside Biomedical Inc will post ($2.03) earnings per share for the current fiscal year.

Your IP Address:

A number of institutional investors have recently modified their holdings of CLSD. A.R.T. Advisors LLC acquired a new position in shares of Clearside Biomedical during the fourth quarter worth $101,000. Tower Research Capital LLC TRC raised its position in shares of Clearside Biomedical by 1,764.2% in the third quarter. Tower Research Capital LLC TRC now owns 9,321 shares of the company’s stock worth $162,000 after buying an additional 8,821 shares during the period. Ellington Management Group LLC acquired a new position in shares of Clearside Biomedical during the fourth quarter worth $203,000. Norges Bank acquired a new position in shares of Clearside Biomedical during the fourth quarter worth $417,000. Finally, State Street Corp raised its position in shares of Clearside Biomedical by 80.7% in the fourth quarter. State Street Corp now owns 102,278 shares of the company’s stock worth $911,000 after buying an additional 45,671 shares during the period. 33.52% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, March 14th. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a research report on Tuesday, March 14th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Tuesday, March 14th. Needham & Company LLC cut their price objective on shares of Clearside Biomedical to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 14th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Clearside Biomedical in a research report on Friday, February 24th. They issued an “overweight” rating and a $19.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Clearside Biomedical presently has a consensus rating of “Buy” and an average price target of $21.80.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

5 Day Chart for NASDAQ:CLSD

Receive News & Ratings for Clearside Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc and related companies with MarketBeat.com's FREE daily email newsletter.